CSIMarket
Company Name or Ticker Symbol
Search for other Categories
 


Exact Sciences Corp  (EXAS)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
 
 

EXAS's Revenue Year on Year Growth by Quarter and Year

Exact Sciences's Revenue results by quarter and year



Select the Comparisons : Select the Ratio:                        
EXAS Revenue (in millions $) FY 2017 FY 2016 FY 2015 FY 2014
IV Quarter December - 99.38 14.42 1.50
III Quarter September - 28.12 12.63 -
II Quarter June 57.65 21.19 8.12 -
I Quarter March 48.36 14.84 4.27 0.29
FY   106.01 163.53 39.44 1.79

Financial Statements
Exact Sciences's second quarter 2017 Revenue $ 57.65 millions EXAS's Income Statement
Exact Sciences's second quarter 2016 Revenue $ 21.19 millions Quarterly EXAS's Income Statement
EXAS's Growth by Division See EXAS's Growth by Segment

EXAS Revenue ( Y/Y Growth %) 2017
2016 2015 2014
IV Quarter December - 589.18 % 861.33 % 44.23 %
III Quarter September - 122.64 % - -
II Quarter June 172.04 % 160.96 % - -
I Quarter March 225.88 % 247.54 % 1372.41 % -72.12 %
FY   - 314.63 % 2103.35 % -



EXAS Revenue Growth Comment
Exact Sciences Corp reported Revenue surge of 172.04% year on year in the second quarter, to $ 57.65 millions, this is lower than Exact Sciences Corp's recent average Revenue surge of 255.25%.

Looking into second quarter results within Medical Laboratories industry 2 other companies have achieved higher Revenue growth. While Exact Sciences Corp' s Revenue doubling of 172.04% ranks overall at the positon no. 137 in the second quarter.



Revenue Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #3
Healthcare Sector #39
Overall #137
Revenue Y/Y Growth Statistics
High Average Low
1351.02 % 255.25 % -100 %
(Mar 31 2015)   (Sep 30 2014)

You need to upgrade your Flash Player

Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
EXAS's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for EXAS's Competitors
Revenue Growth for Exact Sciences's Suppliers
Revenue Growth for EXAS's Customers

You may also want to know
EXAS's Annual Growth Rates EXAS's Profitability Ratios EXAS's Asset Turnover Ratio EXAS's Dividend Growth
EXAS's Roe EXAS's Valuation Ratios EXAS's Financial Strength Ratios EXAS's Dividend Payout Ratio
EXAS's Roa EXAS's Inventory Turnover Ratio EXAS's Growth Rates EXAS's Dividend Comparisons



Companies with similar Revenue doubling for the quarter ending Jun 30 2017 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2017
Zogenix, Inc.  241.24 %$ 241.236 millions
Steadymed Ltd.  239.36 %$ 239.362 millions
Arbutus Biopharma Corp  236.25 %$ 236.246 millions
Apollo Medical Holdings, Inc.  236.05 %$ 236.054 millions
Neos Therapeutics, Inc.  230.57 %$ 230.572 millions
Inovio Pharmaceuticals, Inc.  229.03 %$ 229.027 millions
Chemocentryx, Inc.  219.75 %$ 219.750 millions
Ptc Therapeutics, Inc.  206.80 %$ 206.800 millions
Bellicum Pharmaceuticals, Inc.  203.96 %$ 203.960 millions
Cti Biopharma Corp.  201.93 %$ 201.929 millions
Orexigen Therapeutics, Inc.  199.78 %$ 199.782 millions
Enzon Pharmaceuticals, Inc.  198.20 %$ 198.195 millions
Cytomx Therapeutics, Inc.  182.87 %$ 182.870 millions
Regenxbio Inc.  176.29 %$ 176.295 millions
Hci Viocare  175.23 %$ 175.234 millions
Exact Sciences Corp  172.11 %$ 172.108 millions
Ionis Pharmaceuticals Inc  170.74 %$ 170.736 millions
Novavax Inc  168.74 %$ 168.743 millions
Invitae Corp  156.87 %$ 156.872 millions
Biolargo, Inc.  156.45 %$ 156.446 millions
Rewalk Robotics Ltd.  145.65 %$ 145.655 millions
Viewray, Inc.  133.44 %$ 133.445 millions
Second Sight Medical Products Inc  115.62 %$ 115.622 millions
Novocure Ltd  114.16 %$ 114.164 millions
Geovax Labs, Inc.  111.77 %$ 111.774 millions
Kite Pharma, Inc.  109.64 %$ 109.635 millions
U.s. Stem Cell, Inc.  104.34 %$ 104.345 millions
Innovus Pharmaceuticals, Inc.  99.96 %$ 99.962 millions
Adamis Pharmaceuticals Corp  97.36 %$ 97.363 millions
Biocept Inc  92.95 %$ 92.946 millions